Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
REGN
$747.57
Regeneron Pharmaceuticals
$11.34
1.54%
REGN
Earnings Whisper ®
N/A
4th Quarter December 2022
Consensus: $8.41
Revenue: $3.17 Bil
Thursday
Feb 2
6:30 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Thursday, November 3, 2022
Regeneron Reports Third Quarter 2022 Financial and Operating Results
What do you expect when REGN reports earnings?
Beat
Meet
Miss
Where is REGN's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$748.07
$742.66
$739.44
$734.03
Support
$730.81
$725.40
$722.18
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.
Peers
Vertex Pharmaceuticals
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
Eli Lilly
BioMarin Pharmaceutical
Ultragenyx Pharmaceutical
ImmunoGen
InterCept
Array Technologies
Expectations
›
Regeneron Pharmaceuticals
